ContraFect Announces Restructuring, CEO Resigns
On November 15, 2023, ContraFect (CFRX) implemented a restructuring plan resulting in a reduction to the Company’s workforce from a total of 23 employees to five employees (the...
Neutral
or
ContraFect Corp News & Analysis
-
-
ContraFect Announces $15M Share Offering
ContraFect (CFRX) is offering $15,000,000 of shares of common stock, Class E warrants to purchase shares of common stock and Class F warrants to purchase shares of common stock. The common...
-
ContraFect Announces 7.03M Share Offering by Selling Stockholders
ContraFect (CFRX) has filed for up to 7,034,883 share offering by selling stockholders.
-
ContraFect Announces FDA Clearance of CF-370 IND Application
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides,...
-
ContraFect Announces Submission of IND Application to the FDA for CF-370
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides,...
-
ContraFect Enters Warrant Exercise Transaction for Proceeds of $9.6M
ContraFect (NASDAQ:CFRX) Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and...
-
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens
ContraFect (NASDAQ:CFRX) Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and...
-
ContraFect Announces 7.03M Share Offering by Selling Stockholders
ContraFect (NASDAQ:CFRX) has filed for up to 7,034,883 share offering by selling stockholders.
-
Maxim Group upgrades ContraFect Corp to Buy
A Maxim Group analyst upgraded ContraFect Corp (NASDAQ: CFRX) from Hold to Buy with a price target of $No data. Prior to this rating, ContraFect Corp had buy ratings, hold ratings, and...
-
ContraFect Prices $10M Share Offering at $4/sh, Announces Concurrent Private Placement
ContraFect (NASDAQ:CFRX) Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and...
-
ContraFect Resumes Trading Following Pause, Up 84%
ContraFect (CFRX) Resumes Trading Following Pause, Up 84%
-
ContraFect Corp earnings miss, Revenue Inline in Q3
Investing.com - ContraFect Corp reported on Monday third quarter {{erl-940767||earnings that missed analysts' forecasts and revenue that was inline with expectations. ContraFect Corp...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.46%
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Technology, Utilities and Consumer Services sectors propelled shares higher while losses in the Basic...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.15%
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Healthcare, Consumer Goods and Technology sectors propelled shares higher while losses in the Basic...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.09%
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Telecoms, Industrials and Utilities sectors propelled shares higher. At the close in NYSE, the Dow Jones...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.42%
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Oil & Gas and Telecoms sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
